News
The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new ...
LONDON] British pharmaceutical giant AstraZeneca on Tuesday (Jul 29) said net profit rose 27 per cent in the second quarter, ...
The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:AZN), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...
76% of patients in the Dupixent trial reached ≥75% improvement in eczema severity at 24 weeks. Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI ...
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...
Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV) therapy, the French ...
Baghdad (IraqiNews.com) – The Iraqi Ministry of Health mentioned on Sunday that the agreement with Sanofi, a French ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results